RMD Add to watchlist $228.80 1.89 (-0.82%) Last updated: Apr 16, 2026 00:41
52-Week Range
$228.80
$202.00 $228.80 $293.81

Fundamentals Overview

ResMed Inc. is in the middle of its 52-week range with moderate valuation, trading relatively flat today.

Valuation moderate

P/E 22.6 PEG 1.19 P/B 5.3 P/S 6.19

Intrinsic value (DCF)

+23.6% upside vs price

Profitability

Net margin 27.5%

Risk (Beta)

0.93 — in line vol

Earnings & growth

EPS $10.11 Rev +6.5% Profit +12.6% vs prior qtr

BullzEye Analysis

Our composite tilts Hold on technicals (e.g. RSI, ADX, trend), fundamentals, sentiment, sector and index context, and risk.

Composite Signal

Sell
Buy
Hold — 61% confidence Risk: Moderate Volatility — Beta 0.93. Diversify and only invest what you can afford to lose.

Supporting (Buy):

DCF +23.6% upside vs price · Analyst grade: A- · Sentiment improving (2 upgrades)

Pressures (Sell):

3M vs S&P 500: -12% · 3M vs Healthcare sector: -5.2%

Not financial advice. For education and research only; do your own research and consider a financial advisor before investing.

Key Stats

Market Cap
$33.40B
P/E (TTM)
22.64
EPS (TTM)
$10.11
Dividend Yield
0.52%
52-Week Range
$202.00 - $293.81
Volume vs Avg
N/A
Beta
0.93

About

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other access...
Sector: Healthcare
Headquarters: US
Employees: 9,980
IPO Date: Jun 1995
Beta: 0.93 (Less volatile than market)

Ratings & Grades at a Glance

Overall rating: A-. Recent institutional grades: majority upgrades. Current institutional positions: Buy: 5, Equal Weight: 1, Hold: 5, Neutral: 4, Outperform: 8, Overweight: 6, Sector Perform: 1.

Financial story & AI narrative

Open this tab to load the financial story.

Valuation & Ratios

Valuation, liquidity, and profitability metrics are consolidated here (including ratios that previously appeared in the Financials story). Trailing (TTM) vs forward-looking (e.g. DCF) is noted on each line where it matters.

DCF vs price: DCF estimate is $282.77; current price is $228.80. That’s a +23.6% gap. When the gap is large (e.g. >20%), that’s divergence; when they’re close, that’s convergence. Differences can reflect growth expectations, sector premiums, or conservative vs. optimistic assumptions. Use DCF as one input alongside technicals and sentiment.

Metric Value
Valuation
P/E (TTM) 22.64
DCF value (model) $282.77 (23.6% upside)
PEG (TTM) 1.19
P/B (TTM) 5.3
P/S (TTM) 6.19
P/FCF (TTM) 18.67
Liquidity & enterprise
Current Ratio (TTM) 3.06
Quick Ratio (TTM) 2.32
Cash Ratio (TTM) 1.14
Profitability
ROE (TTM) N/A
ROA (TTM) N/A
Revenue growth (YoY) N/A
Net margin (TTM) 27.53%
Gross margin (TTM) 60.98%
Operating margin (TTM) 33.81%
Debt to equity (TTM) N/A

Latest News

News loads when you open this tab.

Price Target, Ratings & Grades

Analyst price targets, consensus, rating snapshot, and institutional grades for RMD.

Analyst Sentiment at a Glance

A- Sentiment Improving
Buy 5Equal Weight 1Hold 5Neutral 4Outperform 8Overweight 6Sector Perform 1
2 upgrades, 1 downgrade
Price Target Consensus
Current $228.80
Median $291.50
Consensus $292.75
Low consensus $255.00
High consensus $345.00

Stock Grades (Institutions)

Institution Action Previous Grade New Grade Date
Citigroup maintain Buy Buy 2026-04-09
Citigroup maintain Buy Buy 2026-02-02
Piper Sandler maintain Neutral Neutral 2026-01-30
Wells Fargo maintain Equal Weight Equal Weight 2026-01-30
Stifel maintain Hold Hold 2026-01-30
RBC Capital maintain Outperform Outperform 2026-01-30
Stifel maintain Hold Hold 2025-12-18
Baird downgrade Outperform Neutral 2025-12-16
Baird maintain Outperform Outperform 2025-11-03
RBC Capital maintain Outperform Outperform 2025-10-31
Mizuho maintain Outperform Outperform 2025-10-31
Keybanc maintain Overweight Overweight 2025-10-31
Morgan Stanley maintain Overweight Overweight 2025-10-21
Keybanc maintain Overweight Overweight 2025-08-01
Mizuho maintain Outperform Outperform 2025-08-01
UBS maintain Buy Buy 2025-08-01
Piper Sandler maintain Neutral Neutral 2025-08-01
RBC Capital maintain Outperform Outperform 2025-08-01
Stifel maintain Hold Hold 2025-08-01
RBC Capital upgrade Sector Perform Outperform 2025-07-16
Mizuho maintain Outperform Outperform 2025-07-16
RBC Capital maintain Sector Perform Sector Perform 2025-04-24
Keybanc maintain Overweight Overweight 2025-04-24
Piper Sandler maintain Neutral Neutral 2025-04-24
JP Morgan maintain Overweight Overweight 2025-04-24
UBS maintain Buy Buy 2025-04-24
Keybanc maintain Overweight Overweight 2025-04-21
Citigroup upgrade Neutral Buy 2025-03-05
Stifel maintain Hold Hold 2025-03-05
Needham maintain Hold Hold 2025-01-31